PAUL J. SCHMIDT, M.D.
To the editor: All blood collected for transfusion in the United States is now tested to reduce the transmission of non-A, non-B hepatitis (1) by two tests on donor blood that relate statistically to the transmission of the disease. Tests for level of alanine aminotransferase and the presence of hepatitis B core antibody were recommended in 1984 and 1986 (2, 3). The test program (now called surrogate testing) causes the discard of 4% of the nation's blood supply after collection at a cost of about $65 million per year.
The compelling argument that led to the decision to test was
SCHMIDT PJ. Posttranfusion Cirrhosis, Non-A, Non-B Hepatitis, and the Acquired Immunodeficiency Syndrome. Ann Intern Med. ;107:597–598. doi: 10.7326/0003-4819-107-4-597_2
Download citation file:
Published: Ann Intern Med. 1987;107(4):597-598.
Copyright © 2018 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use